Mustang Bio (MBIO) Income from Continuing Operations (2016 - 2026)
Mustang Bio (MBIO) posted quarterly Income from Continuing Operations of 955000.0 for Q1 2026, down 299.58% year-over-year from 478501.05 in Q1 2025, and down 77.51% quarter-over-quarter from 538000.0 in Q4 2025.
Mustang Bio (MBIO) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Income from Continuing Operations for 11 consecutive years, with 955000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 299.58% year-over-year to 955000.0; the TTM figure through Mar 2026 stood at 2723000.0 (up 80.76% YoY), while the FY2025 annual figure was 1921000.0, up 87.8% from the prior year.
- Income from Continuing Operations slipped to 955000.0 in Q1 2026 per MBIO's latest filing, from 538000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 239000.0 in Q1 2025 and bottomed at 22456000.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 9160000.0 across 5 years, with a median of 8615000.0 in 2023.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 95.62% — and 2026, when it slumped 299.58%.
- Mustang Bio's Income from Continuing Operations stood at 22456000.0 in 2022, then jumped by 61.64% to 8615000.0 in 2023, then jumped by 87.46% to 1080000.0 in 2024, then jumped by 50.19% to 538000.0 in 2025, then slumped by 77.51% to 955000.0 in 2026.
- Business Quant data shows MBIO's Income from Continuing Operations at 955000.0 in Q1 2026, 538000.0 in Q4 2025, and 468000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | -1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07 Mn |
| Mar 31, 2026 | -955,000.00 |
| Dec 31, 2025 | -538,000.00 |
| Sep 30, 2025 | -468,000.00 |
| Jun 30, 2025 | -762,000.00 |
| Mar 31, 2025 | -239,000.00 |
| Dec 31, 2024 | -1.08 Mn |
| Sep 30, 2024 | -1.41 Mn |
| Jun 30, 2024 | -11.42 Mn |
| Mar 31, 2024 | -5.46 Mn |
| Dec 31, 2023 | -8.62 Mn |
| Sep 30, 2023 | -10.20 Mn |
| Jun 30, 2023 | -16.66 Mn |
| Mar 31, 2023 | -16.89 Mn |
| Dec 31, 2022 | -22.46 Mn |
| Sep 30, 2022 | -19.67 Mn |
| Jun 30, 2022 | -19.10 Mn |
| Mar 31, 2022 | -19.80 Mn |
| Dec 31, 2021 | -20.05 Mn |
| Sep 30, 2021 | -17.01 Mn |